PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma
PharmAbcine, Inc, a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications announces that the company received “Study May Proceed Letter “ from the US Food and Drug Administration (FDA) for the Investigational New Drug (“IND”) application of its flagship antibody, TTAC-0001. This enables the Company to begin opening US clinical trial sites for phase II clinical trial with bevacizumab (Avastin®) refractory recurrent GBM patients.
Recurrence of GBM is inevitable and recurrent GBM (rGBM) is one of the most aggressive and has the worst prognosis. The treatment options are limited with modest activity for rGBM. Therefore, there is no universally held standard of care available till now.
Patients with rGBM are suffering under cerebral edema and partially responded to bevacizumab. However, patients responded to bevacizumab ultimately become non-responder during the treatment and once patients become bevacizumab non-responder, unfortunately, there are no more therapeutic options.
Cerebral edema comes from excessive secretion of VEGF-A, B, C and D from brain tumors. While bevacizumab traps VEGF-A only, TTAC-0001 binds to VEGFR2 specifically and interferes the activation of VEGFR2 by VEGF-A, C and D.
TTAC-0001 has completed its phase IIa in recurrent GBM in Australia last year with clear safety profile (all DAE maintain within grade 2) and 25% disease control rate. rGBM patients in the study responded to TTAC-0001 for cerebral edema (>40%). No hypertension, hemorrhage, gastric/lung perforation or proteinuria have been observed.
Jin-San Yoo, CEO of PharmAbcine, Inc., commented: “As part of the study design, it was always planned that US trial sites would become part of our Bevacizumab refractory recurrent GBM Phase II clinical trial. We are pleased with today’s IND approval from the FDA as it will accelerate patient enrolment into the global bevacizumab recurrent GBM phase II trial. Moreover, the FDA’s decision is positive news for eligible American sufferers under this devastating condition who can now participate in the study.”
This research was supported by Korea Drug Development Fund (KDDF) funded by MSIT, MOTIE and MOHW (Grant No. KDDF201509-07, Republic of Korea)
About PharmAbcine Inc.
PharmAbcine is a leading clinical stage biologics company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
PharmAbcine’s fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.
Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.
TTAC-0001(=Tanibirumab): anti-KDR neutralizing fully human IgG with unique cross species cross reactivity has completed its Phase IIa recurrent GBM trial in Australia in August 2017. Promising molecule to combine with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.
PMC-001(=DIG-KT): next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to bevacizumab and Tanibirumab in preliminary studies. It also overcomes the Avastin® resistant brain tumor growth. Both PMC-002 and PMC-002R are different scaffolds neutralizing same targets like PMC-001.
PMC-201: next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcomes anti-cancer drug resistant tumor growth.
PMC-005B: Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for codevelopment or out-licensing.
PMC-309a-z: anti-VISTA fully human antibodies collection as either agonistic or antagonistic. Antagonistic antibody performed synergy effects in combination with other immuno-oncology drug.
"3G-System" platform provides high performing production cell lines and we do have both
PMC-901: bevacizumab biosimilar cell line with 3g/L productivity.
PMC-902: aflibercept biosimilar cell line with > 3g/L productivity.
Additional information about PharmAbcine is available through its website, http://www.pharmabcine.com
About GBM, recurrent GBM and Avastin refractory recurrent GBM
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, with a median survival of less than 15 months from diagnosis and recurs frequently within a year following the initial treatment. Chemotherapy, radiation and surgery are the primary initial treatments; chemotherapy and surgery may be possible for recurrent disease, with limitations in using radiation dependent on the site of recurrence. Avastin® is approved as an active treatment option (single agent) for patients with rGBM who have failed previous TMZ and radiation therapy. During Avastin® treatment, some of patients become Avastin® refractory recurrent GBM.
Dr. Sung Woo Kim, 82-42-863-2017
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Business Reply Wins Prestigious Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud23.10.2018 11:00 | Pressemelding
Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business. Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products. T
Hilton Announces Innovative New Hotel Brand; ‘Motto by Hilton’ Will Deliver Affordable Style in Coveted Urban Destinations23.10.2018 11:00 | Pressemelding
Hilton (NYSE:HLT) today announced the launch of Motto by Hilton, its newest affordable lifestyle brand that will empower guests by giving them the freedom to create their own experiences in the world’s most sought-after cities. As Hilton approaches its 100th anniversary, it continues to pioneer the hospitality landscape with a new brand to address the needs and desires of the evolving global traveler. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005378/en/ Motto by Hilton Linked Rooms (Photo: Business Wire) “Hilton prides itself on being a leader in the hospitality industry and evolving with the needs of our guests,” said Christopher J. Nassetta, president and CEO, Hilton. “Innovation is in our DNA, and as we embark on our 100th year as a company, we are innovating more than ever before. With Motto by Hilton, we are bringing to market something the industry has never experienced with its flexible and affordable room
STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells23.10.2018 10:00 | Pressemelding
STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339. mTeSR™1 is an Ancillary Material used in basic and translational research to maintain and expand human pluripotent stem cells (hPSCs) in the undifferentiated state. Used in over 1500 peer-reviewed publications, mTeSR™1 is the most widely published feeder-free cell culture medium, with established protocols for applications ranging from cell line derivation to terminal differentiation. With pre-screened raw materials that ensure batch-to-batch consistency, mTeSR™1 provides robust cultures with homogeneous, undifferentiated phenotypes. “Advancing our cGMP (Current Good Manufacturing Practices) Ancillary Material suite of products is a top priority for STEMCELL. This further demonstrates to our customers that we are a trusted partner for their bench to bedside translational journey,” says
Enevate Secures Funding from LG Chem to Accelerate Fast Charge Li-Ion Battery Technology Development for Electric Vehicles23.10.2018 10:00 | Pressemelding
Enevate Corporation, an advanced lithium-ion (Li-ion) battery technology company, announced that LG Chem, a leading high volume battery manufacturer in South Korea, has participated in Enevate’s recent funding. This investment is a nod to the viability of Enevate’s technology which could enable Electric Vehicles (EVs) to charge in the same time as gas cars without compromise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005147/en/ Enevate’s HD-Energy® Technology for EVs allows Li-ion batteries to be charged to 75 percent capacity in five minutes, while also providing higher energy densities than available for today’s current long-range EVs. They can also safely charge and discharge down to -40°C and capture more energy during regenerative braking, extending their range in cold climates. “The strategic investment from LG Chem indicates the significance of our technology because it could directly address consumer conce
Malta and Austria Are Home to the World’s Best Investment Migration Programs23.10.2018 09:00 | Pressemelding
The Malta Individual Investor Program is the world’s top citizenship-by-investment program and the Austria Private Residence Program is the world’s top residence-by-investment program, according to the Global Residence and Citizenship Programs 2018–2019 report, released today by global residence and citizenship advisory firm Henley & Partners. Dr. Christian H. Kälin, an international immigration and citizenship law expert and Group Chairman of Henley & Partners, says the annual report provides a systematic analysis and comprehensive benchmarking of the world’s most important programs. “It’s an invaluable tool for anyone interested in alternative residence or citizenship as well as for the professionals like private bankers and lawyers who advise them. It also provides governments with a detailed picture of the broader investment migration industry landscape and where they fit it.” Malta is followed in the citizenship program ranking by Cyprus in 2nd place, Austria in 3rd place, and Ant
Temenos Ramps up AI Efforts to Power its Digital Banking Platform23.10.2018 08:30 | Pressemelding
Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention. As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line. Temenos’ pioneering initiative will involve injecting